Patent application number | Description | Published |
20080227836 | Stable Solid Oral Dosage Forms of Valsartan - A stable solid oral dosage form comprising valsartan or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable additives such as sugar (derivatives) and cellulose (derivatives). The active agent is present in an amount less than 35% by weight based on the total weight of the solid oral dosage form. Disclosed is also a process of forming a valsartan-containing composition; which process comprises blending valsartan with pharmaceutically acceptable additives, dry compressing, milling and screening said mixture to obtain granules. Said granules are compressed into tablets and are subsequently coated. | 09-18-2008 |
20090022809 | STABLE TASTE MASKED FORMULATIONS OF CEPHALOSPORINS - A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in α-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the α-crystalline form, wherein the particle size distribution of the α-crystalline form being such that 100% of the particles have a particle size below 250μ. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15μ. The process of preparation of coated, non-disintegrating pellets comprising the steps of reducing the particle size of the one or more cephalosporins, blending with the other excipients, wet granulation, extrusion, spheronization, drying and screening to obtain pellets, said pellets being further coated with one or more layers of film coating to achieve taste masking. | 01-22-2009 |
20090197855 | PHARMACEUTICAL COMPOSITIONS OF CEFDINIR - A chewable tablet dosage form comprising Cefdinir or pharmaceutically acceptable salts thereof for the oral administration of Cefdinir in a manner that is more palatable and less objectionable to population group's especially young children and older patients. A method of preparing the chewable tablets comprising Cefdinir and method of treatment using the same. | 08-06-2009 |
20100009955 | PHARMACEUTICAL COMPOSITIONS OF CEFIXIME - A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients. | 01-14-2010 |
20100272801 | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND VALSARTAN - A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine besylate and valsartan; when administered to human subject, under the bioequivalence parameters of a 90% Confidence Interval for AUC which is between 80% and 125%, and a 90% Confidence Interval for Cmax, which is between 80% and 125%. | 10-28-2010 |
20110020439 | DELAYED RELEASE COMPOSITIONS OF DULOXETINE - A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof; intermediate layer; and enteric layer; wherein the dosage form comprises one/more dissolution enhancer(s), wherein the enteric layer comprises one/more enteric polymers other than hydroxypropylmethyl acetate succinate. A process of preparing a delayed release dosage comprising mixing pharmaceutically acceptable excipients with duloxetine or its pharmaceutically acceptable derivatives thereof; granulating the product of previous step compressing the granulate formed in previous step to form core, coating said core with intermediate layer followed by coating with one/more enteric polymers and optional finishing coating. A delayed release dosage form comprising: core comprising duloxetine or its pharmaceutically acceptable derivative thereof, intermediate layer and enteric layer comprising one/more enteric polymers other than hydroxypropylmethyl acetate succinate; wherein dosage form contains one/more dissolution enhancer(s) and has improved dissolution. | 01-27-2011 |
20110123609 | MULTIPLE UNIT DOSAGE FORM OF NIACIN - A multiple unit dosage form useful for treating or preventing hyperlipidemia and/or atherosclerosis, wherein multiple unit dosage form comprise of a therapeutically effective amount of niacin or its derivatives and one or more control releasing agent(s) and pharmaceutically acceptable excipients, weight percentages are based upon the total weight of the dosage form. The multiple unit dosage form may comprise of optionally other antihyperlipidemic agent, more preferably HMG CoA reductase inhibitor. The most preferable dosage form is capsule. Further a kit comprising one or more capsules co-packaged to provide multiple unit dosage form of niacin or its derivatives in combination with HMG CoA reductase inhibitor is disclosed. | 05-26-2011 |
Patent application number | Description | Published |
20130064891 | PHARMACEUTICAL COMPOSITIONS OF NSAID AND ACID INHIBITOR - The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising Esomeprazole and Naproxen and a process for preparation thereof. Further invention relates to a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients wherein, esomeprazole magnesium dihydrate and non-steroidal anti-inflammatory drug provides co-ordinated release. | 03-14-2013 |
20130143857 | PHARMACEUTICAL COMPOSITIONS OF CEFDITOREN PIVOXIL - The present invention relates to a pharmaceutical composition comprising Cefditoren pivoxil, water soluble high molecular weight substance and one or more pharmaceutically acceptable excipient wherein weight ratio of high molecular weight substance to Cefditoren pivoxil is greater than 1:4 and a process for preparation thereof. | 06-06-2013 |
20140315871 | TOPICAL PHARMACEUTICAL COMPOSITIONS OF ANTI-MICROBIAL AGENTS AND ANTI-INFLAMMATORY AGENTS - The present invention provides sterile, storage-stable topical pharmaceutical compositions intended for application to the eye, ear or nose comprising Dexamethsone and Ciprofloxacin. The topical pharmaceutical compositions of invention comprises combination of ionic tonicity agent and non-ionic tonicity agent(s). The topical pharmaceutical compositions further comprises boric acid. The invention provides a process for preparing and sterilizing the compositions in order to reduce the amount of related compounds and impurities associated with the topical compositions on storage. The topical pharmaceutical compositions of invention found storage-stable, have easy resuspendability. | 10-23-2014 |